期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
茱萸丸调控p53/SLC7A11信号通路介导氧化损伤及铁死亡减轻动脉粥样硬化
1
作者 宋玮 张钟艺 +1 位作者 张小波 沈涛 《中国中药杂志》 CAS CSCD 北大核心 2024年第15期4118-4127,共10页
旨在探讨茱萸丸对动脉粥样硬化(AS)的影响及可能的作用机制。采用高脂饲料喂养诱导小鼠AS模型,造模周期为12周。造模成功的50只载脂蛋白E基因敲除(ApoE^(-/-))小鼠按照随机数字表法分为5组,即模型组,茱萸丸低、中、高剂量组,阿托伐他汀... 旨在探讨茱萸丸对动脉粥样硬化(AS)的影响及可能的作用机制。采用高脂饲料喂养诱导小鼠AS模型,造模周期为12周。造模成功的50只载脂蛋白E基因敲除(ApoE^(-/-))小鼠按照随机数字表法分为5组,即模型组,茱萸丸低、中、高剂量组,阿托伐他汀钙组,每组10只;C57BL/6J小鼠10只作为空白组。空白组及模型组给予等体积无菌蒸馏水灌胃,茱萸丸低、中、高剂量组给予130.54、261.08、522.16 mg·kg^(-1)灌胃,阿托伐他汀钙组给予10.40 mg·kg^(-1)灌胃,每日1次,共12周。给药结束后,采用苏木素-伊红(HE)染色观察小鼠主动脉、肝脏、附睾脂肪的病理学变化,并计算主动脉斑块面积占比、附睾脂肪面积、非酒精性脂肪肝活动性积分(NAS);油红O染色、Masson染色观察主动脉脂质及胶原纤维沉积,并计算主动脉红染脂质面积占比、主动脉胶原沉积面积占比;比色法检测血清超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)、铁离子水平;免疫荧光法检测主动脉环氧合酶2(COX2)、铁蛋白重链1(FTH1)、胱氨酸/谷氨酸逆向转运蛋白溶质载体家族7成员11(SLC7A11)、谷胱甘肽过氧化物酶4(GPX4)蛋白水平;免疫组化法检测主动脉肿瘤蛋白53(p53)水平;蛋白免疫印迹法检测主动脉p53、SLC7A11蛋白表达;实时荧光定量聚合酶链式反应(real-time PCR)检测小鼠主动脉p53、SLC7A11、GPX4、FTH1、前列腺素G/H合酶2(PTGS2)、还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶1(NOX1)mRNA表达水平。结果显示,与空白组比较,模型组小鼠主动脉斑块面积明显扩大,胶原纤维沉积增加,肝脏脂质沉积增加,脂滴变多,附睾脂肪细胞体积扩大;血清中铁离子、MDA含量升高,SOD、GSH-Px水平降低;p53、COX2蛋白表达升高;主动脉FTH1、SLC7A11、GPX4蛋白及mRNA表达降低;PTGS2、NOX1 mRNA表达升高。与模型组比较,茱萸丸低、中、高剂量组及阿托伐他汀钙组小鼠主动脉斑块面积明显缩小,胶原沉积减少,肝脏脂质沉积减少,脂滴变少,附睾脂肪细胞体积缩小;血清中铁离子、MDA含量降低,SOD、GSH-Px水平升高;p53、COX2蛋白表达降低;主动脉FTH1、SLC7A11、GPX4蛋白及mRNA表达升高;PTGS2、NOX1 mRNA表达降低。综上所述,茱萸丸对小鼠AS主动脉斑块具有较好的治疗作用,其机制可能与调控p53/SLC7A11信号通路介导的氧化损伤及抑制细胞铁死亡有关。 展开更多
关键词 动脉粥样硬化 茱萸丸 氧化损伤 铁死亡 肿瘤蛋白53(p53) 胱氨酸/谷氨酸逆向转运蛋白溶质载体家族7成员11(slc7a11)
原文传递
DL-3-n-butylphthalide alleviates motor disturbance by suppressing ferroptosis in a rat model of Parkinson’s disease 被引量:6
2
作者 Chun-Bo Hu Hui Jiang +5 位作者 Yin Yang Guo-Hua Wang Qiu-Hong Ji Zhong-Zheng Jia Li-Hua Shen Qian-Qian Luo 《Neural Regeneration Research》 SCIE CAS CSCD 2023年第1期194-199,共6页
DL-3-n-butylphthalide(NBP)-a compound isolated from Apium graveolens seeds-is protective against brain ischemia via various mechanisms in humans and has been approved for treatment of acute ischemic stroke.NBP has sho... DL-3-n-butylphthalide(NBP)-a compound isolated from Apium graveolens seeds-is protective against brain ischemia via various mechanisms in humans and has been approved for treatment of acute ischemic stroke.NBP has shown recent potential as a treatment for Parkinson’s disease.However,the underlying mechanism of action of NBP remains poorly understood.In this study,we established a rat model of Parkinson’s disease by intraperitoneal injection of rotenone for 28 successive days,followed by intragastric injection of NBP for 14-28 days.We found that NBP greatly alleviated rotenone-induced motor disturbance in the rat model of Parkinson’s disease,inhibited loss of dopaminergic neurons and aggregation ofα-synuclein,and reduced iron deposition in the substantia nigra and iron content in serum.These changes were achieved by alterations in the expression of the iron metabolism-related proteins transferrin receptor,ferritin light chain,and transferrin 1.NBP also inhibited oxidative stress in the substantia nigra and protected mitochondria in the rat model of Parkinson’s disease.Our findings suggest that NBP alleviates motor disturbance by inhibition of iron deposition,oxidative stress,and ferroptosis in the substantia nigra. 展开更多
关键词 cystine/glutamate antiporter solute carrier family 7 member 11 DL-3-n-butylphthalide ferritin light chain ferroportin 1 ferroptosis glutathione peroxidase 4 oxidative stress iron ROTENONE transferrin receptor
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部